tracken
Bristol-Myers Squibb Aktie News
Positiv
CNBC
●
12 Tage alt
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Positiv
The Motley Fool
●
14 Tage alt
Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.
Neutral
Business Wire
●
19 Tage alt
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference.
Positiv
The Motley Fool
●
21 Tage alt
Great dividend payers can support and raise their payouts through the years. VICI Properties is a leading REIT with a vast portfolio of experience-oriented properties.
Positiv
Schaeffers Research
●
22 Tage alt
Subscribers to Chart of the Week received this commentary on Sunday, Dec, 28.
Negativ
The Motley Fool
●
22 Tage alt
Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, including several patent cliffs.
Positiv
The Motley Fool
●
22 Tage alt
Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device maker that's nearing Dividend King status.
Positiv
The Motley Fool
●
25 Tage alt
Eli Lilly is currently leading the market for GLP-1 drugs, taking the pole position from Novo Nordisk. Novo Nordisk just got approval for a GLP-1 pill, which could again upend the dynamics for weight loss drugs.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
